Samyang Biopharm is specialized in commercialization of first generics and drug delivery system (DDS)-based modified drugs for cancer tratment and development of small-molecule drugs, new biologic drugs, and cancer virus vaccines. 

Samyang Biopharm is exporting its oncology products to more than 25 countries and its cytotoxic manufacturing facility is authorized by authorities from Korea, Europe, and Japan. To expand its Contract Development & Manufacturing, Samyang Biopharm is constructing a new facility which is expected to achieve full cGMP operation and the construction will be completed in 2020. Furthermore, it continues to enhance its product portfolio to meet the latest pharmaceutical trends. 


In October, 2018, it established Samyang Biopharm USA Inc. in Cambridge, USA and drives to enter into U.S market mainly for pharmaceutical developmentof immune-oncology and rare diseases. 


Samyang Biopharm manufactures Cytotoxic APis, Cytotoxic Injections, Transdermal Patches, and offers CDMO services. 
If you would like to know more about Samyang, click "request info" or click brochures and videos. 

Sales Markets

Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)

Contact information

Address

Telephone

Website

View All Contact Info

Top Products

APIs

APIs

Samyang Biopharmaceuticals Corp

CDMO service

CDMO service

Samyang Biopharmaceuticals Corp

FDFs

FDFs

Samyang Biopharmaceuticals Corp

Our Resources

Categories affiliated with Samyang Biopharmaceuticals Corp